Current standard of care and recent progress in recurrent/metastatic endometrial cancer.

Endometrial cancer is the sixth most common female tumor, with both incidence and mortality increasing worldwide. Although the localized disease is curable by surgery, with a five-year overall survival rate of 96%, in advanced stages the five-year survival rate drops to less than 20%. Platinum-based chemotherapy represented the standard of care in first-line chemotherapy, but 50% of patients progressed within one year. Today, because of the newest classification of four molecular subgroups of endometrial cancer, we can identify patients who can benefit from immunotherapy or targeted therapy, and we can offer those women a longer overall survival rate, with a better quality of life. The recent advances in immunotherapy opened other options for women with the MSI subset of tumors and, given the wealth of targets in endometrial cancer, the challenge will be to choose the proper treatment and sequencing to obtain the best outcome in the first or second line of therapy for our patients. Since endometrial cancer is the only gynecologic cancer with an increasing incidence and death rate, it is crucial to identify effective treatments and to find therapeutic combinations that can improve the medication performance while reducing drugs toxicities. [ABSTRACT FROM AUTHOR]